MONOCLONAL ANTIBODY, POLYNUCLEOTIDE, COMPOSITION, MIXTURE, USE OF A MONOCLONAL ANTIBODY OR A FUNCTIONAL PART OF THE SAME, METHOD FOR PREPARING A PHARMACEUTICAL COMPOSITION, ISOLATED HYBRIDOMA CELL LINING, A DAYTIME METHOD OF EMERGENCY TO DIAGNOSE A PREDISPOSITION FOR A DISEASE OR CONDITION, METHOD FOR MONITORING MINIMUM RESIDUAL DISEASE, METHOD FOR PREVENTING A PATIENT'S RESPONSIVENESS AND TEST KITS

摘要

monoclonal antibody, polynucleotide, light chain variable region, heavy chain variable region, composition, mixture, methods for producing an antibody, for preparing a pharmaceutical composition or mixture, for diagnosing an amyloid-associated disease or condition, to determine the degree of amyloidogenic plaque load on a tissue, to diagnose a predisposition to a disease or condition, to monitor minimal residual disease and to predict a patient's responsiveness, use of a monoclonal antibody and / or a functional part of it and / or a pharmaceutical composition or mixture, hybridoma cell line, and test kits. the present invention relates to methods and compositions for therapeutic and diagnostic use in the treatment of diseases and disorders that are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as alzheimer's. the present invention provides new methods and compositions comprising highly specific and highly effective antibodies having the ability to recognize and specifically bind to specific epitopes of a variety of (beta) amyloid proteins. the antibodies made possible by the teachings of the present invention are particularly useful for the treatment of diseases and disorders that are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and amyloidosis age-related including, but not limited to, neurological disorders such as alzheimer's disease (ad).